ST Pharm Co (237690) Fair Value & Analysis
Healthcare · KR · Market cap 2.6T KRW
Fair value as of: Jul 12, 2026
From 15 valuation models · updated 29 days ago
Share price −16.7% over the past month.
Below-average quality, and screening another 50% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (62,638 KRW). The favourable scenario is already priced in.
- Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range 59,476 KRW – 168,700 KRW · fair‑value band 37,583 KRW – 62,638 KRW · the 100,100 KRW price screens above the 50,110 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 12, 2026.
Analysis
ST Pharm Co (237690) currently trades at 100,100 KRW, while our model-based Fair Value estimate is 50,110 KRW, implying the stock looks roughly 49.9% overvalued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, ST Pharm Co generated revenue of 201B KRW at a net margin of 5.5%. Revenue grew 31.4% year over year. Net debt stands at 46.0B KRW. Fundamentals as of Jul 12, 2026
Our scenario range runs from 37,583 KRW (bear case) to 62,638 KRW (bull case); at 100,100 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 32% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -19% fair-value upside, at -50%, 237690 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: Growth Earnings (73,028 KRW) versus Asset-Based (21,313 KRW). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 35
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea.
Full company description
ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It also provides oligonucleotide based products, such as antisense, siRNA, miRNA, aptamer, CpG, decoy, and other products; and monomer/phosphoramidite. In addition, the company offers generic APIs for anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppressant, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medicines, as well as MRI contrast agents. Further, it provides 2nd battery, electronic materials, and polymer catalysts. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is based in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ST Pharm Co reported revenue of 332B KRW in FY2025 versus 166B KRW in FY2021, a compound +19.0%/yr. Reported net income was 55.0B KRW in FY2025, compounding +101.9%/yr from FY2021.
237690 screens 50% overvalued. Compare with GlaxoSmithKline Pharmaceuticals Limited →
Peer Group
Pharmaceuticals · 25 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Limited 500660 | ₹2,653 | ₹1,471 | -45% |
| Caregen Co 214370 | 62,700 KRW | 7,277 KRW | -88% |
| Oscotec Inc 039200 | 31,050 KRW | 25,062 KRW | -19% |
| DongKook Pharmaceutical Co 086450 | 18,350 KRW | 32,142 KRW | +75% |
| Kolon Life Science Inc 102940 | 30,100 KRW | 37,195 KRW | +24% |
| Huons Global Co 084110 | 23,800 KRW | 58,482 KRW | +146% |
| BINEX Co 053030 | 6,350 KRW | 1,844 KRW | -71% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 16,810 KRW | 4,741 KRW | -72% |
| EURO EURO | 1.09 PHP | 0.8700 PHP | -20% |
| Kyung Dong Pharmaceutical Co 011040 | 4,935 KRW | 6,165 KRW | +25% |
Compare ST Pharm Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ST Pharm Co (237690) overvalued or undervalued?
What is the fair value of 237690?
What is the quality score of 237690?
What is the revenue of ST Pharm Co (237690)?
What is the net profit margin of 237690?
Does ST Pharm Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track ST Pharm Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.